We are excited to present preclinical data at #ASCO2024 from Rgenta’s RGT-61159 program demonstrating significant antitumor data in several patient derived xenograft (PDX) models of adenoid cystic carcinoma (ACC). ACC is an aggressive, difficult to treat tumor that arises in the salivary glands and is associated with the aberrant expression of MYB, a master regulator of cell proliferation and differentiation. RGT-61159, identified using Rgenta’s integrative RNA-targeting platform, is an orally available small molecule inhibitor of the expression of MYB. Rgenta is developing RGT-61159 for the potential treatment of ACC and other cancers driven by MYB dysregulation, including colorectal cancer (CRC), other solid tumor types and hematologic cancers such as acute myeloid leukemia (AML). Learn more here: https://rgentatx.com/news/
Rgenta Therapeutics Inc.
Biotechnology Research
Woburn, Massachusetts 4,104 followers
We unlock the therapeutic potentials of highly disease-relevant targets undruggable by small molecules.
About us
Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. Our proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glues to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Our lead programs and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases.
- Website
-
http://www.rgentatx.com
External link for Rgenta Therapeutics Inc.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Woburn, Massachusetts
- Type
- Privately Held
- Founded
- 2020
Locations
-
Primary
Get directions
300 TRADECENTER
Suite 6600
Woburn, Massachusetts 01801, US
-
Get directions
700 Main St
Cambridge, Massachusetts(MA) 02139, US
Employees at Rgenta Therapeutics Inc.
Updates
-
Rgenta Therapeutics to Present at the 19th Annual Huntington’s Disease Therapeutics Conference. https://bit.ly/3I8gyRN #HuntingtonsDisease #RepeatExpansionDisease #REDs
-
-
Every February 4th is #WorldCancerDay! A day to raise worldwide awareness, improve education and reimagine a world without cancer. https://bit.ly/2E0iGLK #CloseTheCareGap #Oncology
-
-
Rgenta Therapeutics Joins The Leukemia & Lymphoma Society Therapy Acceleration Program® https://prn.to/3HHRgdk The Leukemia & Lymphoma Society #LLSTAP #RNATargeting #SmallMolecule #Oncology
-
Rgenta Therapeutics Inc. reposted this
We are excited for the opportunity to participate in an engaging event that unites large pharma, innovative biotech & leading academics dedicated to accelerating small molecule drugs targeting RNA. #oncology #neurology
-
-
We are excited for the opportunity to participate in an engaging event that unites large pharma, innovative biotech & leading academics dedicated to accelerating small molecule drugs targeting RNA. #oncology #neurology
-
-
Representing the Rgenta team, Heather Sadlish, our Executive Director of Target Biology, was thrilled to attend as a Speaker at the Myotonic Dystrophy Foundation Conference on Sept 9, 2023 in D.C. Dr. Sadlish’s presented: “Targeting Mismatch Repair Pathways to Treat Repeat Expansion Diseases such as DM1”. #myotonicDystrophy #MDF2023 #myotonicdystrophyawareness #myotonicstrong
-